Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X, Tu S, Wang C, Huang R, Deng L, Song C, Yue C, He Y, Yang J, Liang Z, Wu A, Li M, Zhou W, Du J, Guo Z, Li Y, Jiao C, Liu Y, Chang LJ, Li Y.
Zhou X, et al. Among authors: liang z.
Front Immunol. 2020 Nov 27;11:564099. doi: 10.3389/fimmu.2020.564099. eCollection 2020.
Front Immunol. 2020.
PMID: 33329526
Free PMC article.
Clinical Trial.